Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Drug manufacturing

Printed levetiracetam pill approved for use by the FDA

Printed levetiracetam pill approved for use by the FDA

Source: Aprecia Pharmaceuticals

Spritam is manufactured using a 3D printing technology called ZipDose that enables the delivery of a high drug load, up to 1,000mg, in a single porous formulation

The US Food and Drug Administration (FDA) has given the go-ahead to a 3D printed pill containing the epilepsy drug levetiracetam.

Aprecia Pharmaceuticals’ Spritam, licensed as adjunctive therapy for partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy, is manufactured using a 3D printing technology called ZipDose.

The technique enables the delivery of a high drug load, up to 1,000mg, in a single porous formulation. According to Aprecia Pharmaceuticals, the formulation marks a breakthrough for patients who may have difficulty swallowing their medication because the printed pill rapidly disintegrates when taken with a sip of water.

“By combining 3D printing technology with a highly prescribed epilepsy treatment, Spritam is designed to fill a need for patients who struggle with their current medication,” says company chief executive officer Don Wetherhold. “This is the first in a line of central nervous system products Aprecia plans to introduce.”

The company expects the product to be available in the United States in spring 2016 and is currently evaluating other possible markets.

A spokesperson for the FDA confirmed that Spritam is the first 3D-printed tablet it has approved.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069122

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.